AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12518847 — intervention group
Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 0
Study 9615306 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (1%) aerosol
Number of subjects: 80
Study 9615306 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide aerosol (100 mg)
Number of subjects: 80
Study 7856472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (1 mg/Kg/day)
Number of subjects: 14
Study 7856472 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg/day)
Number of subjects: 14
Study 2610509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime alone (400 mg)
Number of subjects: 12
Study 2610509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime simultaneous with antacid (Maalox; 20 ml)
Number of subjects: 12
Study 2610509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 2 h before antacid
Number of subjects: 12
Study 2610509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 2 h after antacid
Number of subjects: 12
Study 4552594 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis
Number of subjects: 304
Study 4552594 — intervention group
Group type: COMPARATOR
Intervention: Human diagnosis by the most senior member of the clinical team
Number of subjects: 304
Study 31826360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 726
Study 31826360 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 726
Study 31323516 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL (Hybrid Assistive Limb)
Number of subjects: 37
Study 31323516 — intervention group
Group type: COMPARATOR
Intervention: CP (Conventional Physical therapy)
Number of subjects: 37
Study 28606907 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 120
Study 28606907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula Therapy (HFNC)
Number of subjects: 120
Study 28606907 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 120
Study 25193390 — intervention group
Group type: EXPERIMENTAL
Intervention: Transenteral (TE) bowel preparation
Number of subjects: 100
Study 25193390 — intervention group
Group type: COMPARATOR
Intervention: Peroral (PO) bowel preparation
Number of subjects: 100
Study 23470209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and carboxymethylcellulose (HA/CMC) instillation
Number of subjects: 120
Study 23470209 — intervention group
Group type: COMPARATOR
Intervention: Lubricant instillation (control)
Number of subjects: 120
Study 22093203 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily
Number of subjects: 88
Study 22093203 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg daily
Number of subjects: 88
Study 19592108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15%
Number of subjects: 120
Study 19592108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2%
Number of subjects: 120
Study 19592108 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 120
Study 16837920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (1.0 mM)
Number of subjects: 51
Study 16837920 — intervention group
Group type: COMPARATOR
Intervention: Control calcium dialysate (1.62 mM)
Number of subjects: 51
Study 12780410 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Deviation (MD)
Number of subjects: 316
Study 12780410 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of significant points
Number of subjects: 316
Study 10951511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (350‐400 IU)
Number of subjects: 141
Study 10951511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(1) supplementation (80 microg)
Number of subjects: 141
Study 10951511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 9138625 — intervention group
Group type: EXPERIMENTAL
Intervention: Shy participants
Number of subjects: 30
Study 9138625 — intervention group
Group type: COMPARATOR
Intervention: Outgoing participants
Number of subjects: 30
Study 8223351 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone, 0.5 mg kg‐1 bolus followed by continuous infusion of 5 micrograms kg‐1 min‐1
Number of subjects: 25
Study 8223351 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine, 7 micrograms kg‐1 min‐1
Number of subjects: 25
Study 8223351 — intervention group
Group type: COMPARATOR
Intervention: Dopamine, 5 micrograms kg‐1 min‐1
Number of subjects: 25
Study 3780161 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g (sodium salt)
Number of subjects: 12
Study 3780161 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin 4 g (sodium salt)
Number of subjects: 12
Study 29853660 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 706 (motesanib) 125 mg per day orally combined with octreotide long acting-repeatable (LAR)
Number of subjects: 44
Study 27193748 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) infusion (5 mg)
Number of subjects: 63
Study 24525316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 136
Study 24525316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 22014477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive early passive rehabilitation (manual therapy 2 times per day and unlimited self-passive stretching exercise) in group A (30 shoulders)
Number of subjects: 64
Study 22014477 — intervention group
Group type: COMPARATOR
Intervention: Limited early passive rehabilitation (limited continuous passive motion exercise and limited self-passive exercise) in group B (34 shoulders)
Number of subjects: 64
Study 22014477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive early passive rehabilitation (group A)
Number of subjects: 64
Study 22014477 — intervention group
Group type: COMPARATOR
Intervention: Limited early passive rehabilitation (group B)
Number of subjects: 64
Study 20399945 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinylestradiol/2 mg chlormadinone acetate (EE/CMA)
Number of subjects: 165
Study 20399945 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinylestradiol/0.15 mg desogestrel (EE/DSG)
Number of subjects: 165
Study 20399945 — intervention group
Group type: COMPARATOR
Intervention: 0.03 mg ethinylestradiol/0.15 mg levonorgestrel (EE/LNG)
Number of subjects: 165
Study 20399945 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 165
Study 18029456 — intervention group
Group type: EXPERIMENTAL
Intervention: AA mixture
Number of subjects: 16
Study 18029456 — intervention group
Group type: COMPARATOR
Intervention: ARG + LYS
Number of subjects: 16
Study 18029456 — intervention group
Group type: COMPARATOR
Intervention: Complete soy protein
Number of subjects: 16
Study 18029456 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed soy protein
Number of subjects: 16
Study 18029456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18029456 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose concentrations
Number of subjects: 16
Study 15963168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnically tailored initial letters
Number of subjects: 4659
Study 15963168 — intervention group
Group type: COMPARATOR
Intervention: General letters
Number of subjects: 4659
Study 15963168 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish‐speaking Latinos
Number of subjects: 4659
Study 15963168 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Latino whites
Number of subjects: 4659
Study 15963168 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 4659
Study 15963168 — intervention group
Group type: EXPERIMENTAL
Intervention: English‐speaking Latinos
Number of subjects: 4659
Study 12452517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizer
Number of subjects: 118
Study 12452517 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide
Number of subjects: 118
Study 10508879 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 268
Study 10508879 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 268
Study 10508879 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm labor without pPROM)
Number of subjects: 268
Study 10508879 — intervention group
Group type: COMPARATOR
Intervention: Control group (term labor)
Number of subjects: 268
Study 10508879 — intervention group
Group type: COMPARATOR
Intervention: Control group (term PROM)
Number of subjects: 268
Study 10508879 — intervention group
Group type: COMPARATOR
Intervention: Control group (term cesarean section)
Number of subjects: 268
Study 7782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics, vasodilators, cardiac glycosides, and other inotropes
Number of subjects: 0
Study 7782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical devices for support of the heart and circulation
Number of subjects: 0
Study 1773423 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl
Number of subjects: 19
Study 1773423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6184898 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate-mesilate (synthetic protease inhibitor)
Number of subjects: 0
Study 6184898 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 0
Study 31675175 — intervention group
Group type: EXPERIMENTAL
Intervention: H&E stain
Number of subjects: 32
Study 31675175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Pap stain
Number of subjects: 32
Study 31675175 — intervention group
Group type: EXPERIMENTAL
Intervention: Giemsa stain
Number of subjects: 32
Study 31675175 — intervention group
Group type: EXPERIMENTAL
Intervention: Feulgen stain
Number of subjects: 32
Study 31675175 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch imprint cytology for lymph nodes
Number of subjects: 32
Study 31801630 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional task exercise group
Number of subjects: 59
Study 31801630 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training group
Number of subjects: 59
Study 31801630 — intervention group
Group type: COMPARATOR
Intervention: Exercise training group
Number of subjects: 59
Study 31801630 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59
Study 28342683 — intervention group
Group type: EXPERIMENTAL
Intervention: White grape juice
Number of subjects: 40
Study 28342683 — intervention group
Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 40
Study 26438129 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold Standard Program (GSP) for smoking cessation intervention
Number of subjects: 32
Study 26438129 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 32
Study 23433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Raft-construct outside the plate
Number of subjects: 3
Study 23433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-locking raft screws through the plate
Number of subjects: 3
Study 23433659 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking raft screws through the plate
Number of subjects: 3
Study 23433659 — intervention group
Group type: COMPARATOR
Intervention: Combined groups using screws through the plate (Groups 2+3)
Number of subjects: 3
Study 21336159 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple eradication and iron supplementation
Number of subjects: 110
Study 21336159 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple sequential eradication
Number of subjects: 110
Study 21336159 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 110
Study 21336159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 21336159 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradicated infection
Number of subjects: 110
Study 21336159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxin-associated gene product A negative strains
Number of subjects: 110
Study 19710072 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope laryngoscope
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils fibrescope
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: CTrach intubating laryngeal mask airway
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anaesthetists
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant anaesthetists
Number of subjects: 63
Study 19710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 63
Study 16616884 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min rest break added to every working hour (experimental condition)
Number of subjects: 82
Study 16616884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional rest breaks)
Number of subjects: 82
Study 15884476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (frozen gel band)
Number of subjects: 31
Study 15884476 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 31
Study 15884476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 31
Study 15884476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and Acetaminophen
Number of subjects: 31
Study 11996608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol (upper vs lower tertile)
Number of subjects: 11177
Study 11996608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (upper vs lower tertile)
Number of subjects: 11177
Study 11996608 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (upper vs lower tertile)
Number of subjects: 11177
Study 11996608 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of serum cholesterol contained in HDL (upper vs lower tertile)
Number of subjects: 11177
Study 9789769 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (TRT)
Number of subjects: 72
Study 9789769 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 72
Study 7626573 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave diode (810 nm)
Number of subjects: 40
Study 7626573 — intervention group
Group type: COMPARATOR
Intervention: Free running neodymium:yttrium aluminium garnet (Nd:YAG) laser (1064 nm)
Number of subjects: 40
Study 2146634 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1000 mu g)
Number of subjects: 11
Study 2146634 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized placebo
Number of subjects: 11
Study 363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (2 mg/kg, intramuscularly every 12 h for 7 to 10 days)
Number of subjects: 57
Study 363053 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg, intramuscularly every 12 h for 7 to 10 days)
Number of subjects: 57
Study 30645696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 100
Study 30645696 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 100
Study 28753762 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use after diagnosis
Number of subjects: 6537
Study 28753762 — intervention group
Group type: COMPARATOR
Intervention: Statin use before diagnosis
Number of subjects: 6537
Study 25864876 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour PIRRT sessions (G1)
Number of subjects: 75
Study 25864876 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour PIRRT sessions (G2)
Number of subjects: 75
Study 23958252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 10 mg
Number of subjects: 407
Study 23958252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 40 mg
Number of subjects: 407
Study 23958252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 100 mg
Number of subjects: 407
Study 23958252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) 300 mg
Number of subjects: 407
Study 23958252 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (ANA) co-administered with atorvastatin (ATV) 10 mg
Number of subjects: 407
Study 23958252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 21829926 — intervention group
Group type: COMPARATOR
Intervention: Version 1 of the sentence list
Number of subjects: 120
Study 21829926 — intervention group
Group type: EXPERIMENTAL
Intervention: All sentence versions
Number of subjects: 120
Study 19488997 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (n = 53)
Number of subjects: 82
Study 19488997 — intervention group
Group type: COMPARATOR
Intervention: General diabetes education (n = 29)
Number of subjects: 82
Study 17284629 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 191
Study 17284629 — intervention group
Group type: COMPARATOR
Intervention: Medical observation
Number of subjects: 191
Study 14757293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with rosiglitazone (8 mg per day) and glibenclamide (7.5 mg per day)
Number of subjects: 340
Study 14757293 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide monotherapy (up-titration to maximum dose of 15 mg per day)
Number of subjects: 340
Study 11383790 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive saphenous vein harvest
Number of subjects: 40
Study 11383790 — intervention group
Group type: COMPARATOR
Intervention: Traditional (open) saphenous vein harvest
Number of subjects: 40
Study 9401408 — intervention group
Group type: EXPERIMENTAL
Intervention: Elster's polyps
Number of subjects: 31
Study 9401408 — intervention group
Group type: COMPARATOR
Intervention: Hyperplastic polyps
Number of subjects: 31
Study 9401408 — intervention group
Group type: COMPARATOR
Intervention: Randomly chosen gastric biopsy specimens
Number of subjects: 31
Study 7968551 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular disparity between objects and angular distance from the vertical axis
Number of subjects: 0
Study 7968551 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects rotated in depth
Number of subjects: 0
Study 7968551 — intervention group
Group type: EXPERIMENTAL
Intervention: Searching for matching ends of figures (Experiments 1 and 2)
Number of subjects: 0
Study 7968551 — intervention group
Group type: EXPERIMENTAL
Intervention: Evident matching ends (Experiment 3)
Number of subjects: 0
Study 3311648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 14
Study 3311648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28560489 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadcast of the Holy Quran with translation
Number of subjects: 168
Study 28560489 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadcast of the Holy Quran without translation
Number of subjects: 168
Study 28560489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 168
Study 29721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 200 mg
Number of subjects: 52
Study 29721574 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 400 mg
Number of subjects: 52
Study 29721574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29721574 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin 400 mg
Number of subjects: 52
Study 28441958 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg per day)
Number of subjects: 0
Study 28441958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25545821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free bicarbonate (AF) dialysis fluid
Number of subjects: 22
Study 25545821 — intervention group
Group type: COMPARATOR
Intervention: Standard acetate-containing bicarbonate (AC) dialysis fluid
Number of subjects: 22
Study 24044798 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery plus radiotherapy (BCS+RT)
Number of subjects: 9231
Study 24044798 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy without radiotherapy (MST-only)
Number of subjects: 9231
Study 24044798 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy plus radiotherapy (MST+RT)
Number of subjects: 9231
Study 20514832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (sugarless) for 30 minutes thrice daily until resumption of intestinal transit
Number of subjects: 46
Study 20514832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 46
Study 19031320 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps magnetic stimulation training for 8 weeks
Number of subjects: 0
Study 19031320 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 0
Study 16816481 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated vitamin D(3)
Number of subjects: 0
Study 16816481 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil (non-thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: P60 (non-thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (non-thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire (non-thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: Z250 (non-thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil (thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: EXPERIMENTAL
Intervention: P60 (thermocycled)
Number of subjects: 60
Study 14653296 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (thermocycled)
Number of subjects: 60